Myriad Genetics (MYGN) Reports In-Line Q2 EPS, misses on revenue, provides guidance

August 3, 2023 4:30 PM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $183.5 million versus the consensus estimate of $187.07 million.


Myriad Genetics sees FY2023 EPS of ($0.36)-($0.24). Myriad Genetics sees FY2023 revenue of $730-750 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities